BioCentury | Aug 8, 2011
Product Development

HIV Trojan horse

HIV's ability to hide out in the body in places that drugs can't reach has helped the virus remain resistant to eradication. But Virxsys Corp. thinks its VRX1273 may be able to provide a functional...
BC Week In Review | Oct 4, 2010
Clinical News

Virxsys preclinical data

Prophylactic VRX1116, a simian analog of VRX1273, led to undetectable viral replication in 2 of 5 rhesus macaques at 13 months post-challenge with simian immunodeficiency virus (SIV) and produced stable or increased CD4+ T cell...
BC Week In Review | Aug 9, 2010
Clinical News

Virxsys preclinical data

In rhesus macaques, prophylactic VRX1273 improved immune responses and led to significant control of viral load over the 4 months following challenge with simian immunodeficiency virus (SIV) vs. unvaccinated controls. Additionally, there were no adverse...
Items per page:
1 - 3 of 3